KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $25.00 Consensus PT from Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has received a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $23.80.

Several brokerages recently commented on KALV. Bank of America began coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target on the stock. TD Cowen initiated coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target on the stock. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 8,077 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,291 shares of company stock worth $304,086. 10.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its stake in KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares during the last quarter. Susquehanna Fundamental Investments LLC boosted its holdings in shares of KalVista Pharmaceuticals by 323.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company’s stock valued at $807,000 after buying an additional 52,347 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $153,000. China Universal Asset Management Co. Ltd. grew its position in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after buying an additional 3,328 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its stake in shares of KalVista Pharmaceuticals by 23.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after acquiring an additional 121,615 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $9.62 on Friday. The business’s 50 day moving average price is $8.80 and its 200-day moving average price is $10.76. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $16.88. The company has a market cap of $475.40 million, a P/E ratio of -2.64 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. As a group, equities analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).